Drugs / 68Ga-NOTA-3P-TATE-RGD
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT02817945 | Jun 2016 → Dec 2020 | lung cancer, neuroendocrine neoplasm | Peking Union Medical College Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-NOTA-3P-TATE-RGD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02817945 ↗ |
| Modality | Peptide | “a heterodimeric peptide TATE-RGD was synthesized from TATE and RGD through a glutamate linker and then labeled with 68Ga.” NCT02817945 ↗ |
| Route | Intravenous | “will be injected intravenously.” NCT02817945 ↗ |